OXLD1: A Potential Drug Target and Biomarker (G339229)

Target Name: OXLD1

NCBI ID: G339229

OXLD1

OXLD1: A Potential Drug Target and Biomarker

Oxidoreductase-like domain-containing proteins (ORDs) are a family of proteins that possess significant involvement in various cellular processes. These proteins are known to play a crucial role in the detoxification of harmful reactive oxygen species (ROS) and have been implicated in a wide range of biological processes, including aging, neurodegenerative diseases, and diseases associated with oxidative stress. OXLD1 is a typical ORD protein that has been identified as a potential drug target and biomarker.

The OXLD1 Protein

OXLD1 is a 17 kDa protein that is expressed in various tissues and organs, including liver, muscle, and brain. It is localized to the endoplasmic reticulum (ER) and has been shown to localize to the endoplasmic reticulum in a variety of cell types, including cancer cells. OXLD1 has been shown to play a role in the detoxification of ROS, which are highly reactive molecules that can cause damage to cells when they accumulate in the body.

The OXLD1 gene

The OXLD1 gene is located on chromosome 6 and encodes a protein that contains a unique ORD domain. This domain is known as the N-terminus of the protein and is responsible for its localization to the ER. The ORD domain is a transmembrane domain that is characterized by a long amino acid sequence that is involved in various cellular processes, including the detoxification of ROS.

Function and localization

OXLD1 is involved in the detoxification of ROS, which are highly reactive molecules that can cause damage to cells when they accumulate in the body. This is accomplished by the OXLD1 protein, which contains a unique ORD domain that is responsible for its localization to the ER. The ORD domain is a transmembrane domain that is characterized by a long amino acid sequence that is involved in various cellular processes, including the detoxification of ROS.

Expression and localization

OXLD1 is expressed in various tissues and organs, including liver, muscle, and brain. It is primarily localized to the ER and has been shown to localize to the endoplasmic reticulum in a variety of cell types, including cancer cells. OXLD1 has also been shown to be expressed in various types of cancer, including lung, colon, and breast cancer.

Drug targeting

Due to its involvement in the detoxification of ROS and its localized to the ER, OXLD1 has been identified as a potential drug target. Drugs that are able to inhibit the activity of OXLD1 have been shown to have potential therapeutic benefits in a variety of diseases, including cancer. For example, studies have shown that inhibiting the activity of OXLD1 has the potential to enhance the effectiveness of chemotherapy in various types of cancer.

Biomarker

OXLD1 has also been identified as a potential biomarker for a variety of diseases, including cancer. This is because the levels of OXLD1 have been shown to be elevated in a variety of cancer types, including breast, lung, and colorectal cancer. This suggests that OXLD1 may be a useful biomarker for the diagnosis and treatment of cancer.

Conclusion

In conclusion, OXLD1 is a protein that is involved in the detoxification of ROS and has been identified as a potential drug target and biomarker. Its localization to the ER and its involvement in the detoxification of ROS make it a promising target for the development of new therapeutic drugs. Further research is needed to fully understand the role of OXLD1 in

Protein Name: Oxidoreductase Like Domain Containing 1

The "OXLD1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about OXLD1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets